Helicobacter pylori colonizes mucosa, activates Toll-like and Nod-like receptors, and usually elicits a gastric T-helper 1/17 (Th1/Th17) type of immune response. Among several bacterial factors, the secreted peptidyl prolyl cis, trans-isomerase of H. pylori represents a key factor driving Th17 inflammation. A complex and fascinating balance between H. pylori and host factors takes part in the gastric niche and is responsible for the chronicity of the infection. Novel insights into the innate and adaptive responses against H. pylori, dealing with gastric epithelial cells, cytokines, and immune evasion have been elucidated over the past year and are discussed for the development of an effective vaccine.Helicobacter pylori chronically infects the stomach of more than half of the human population and represents the major cause of gastroduodenal diseases. However, only 15-20% of H. pylori-infected patients develop severe pathologies, such as gastric cancer, gastric B-cell lymphoma, peptic ulcer, or gastric autoimmunity, during their lifetime. This fact suggests that the type of immunity elicited by H. pylori may represent an important factor that is able to influence the outcome of the infection toward protection, evasion, or pathology. Here, we present an overview of the major findings on the host response to H. pylori published over the past year.